News

Public · Published

Canaccord Genuity maintains AtriCure at Buy, raises price target to $67 from $55

Canaccord Genuity kept its Buy rating on AtriCure and raised its price target to $67 from $55, a 21.8% increase. The new target implies 2.2% upside from the November 4 closing price of $65.53.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on AtriCure and raised its price target to $67 from $55, a 21.8% increase. The new target implies 2.2% upside from the November 4 closing price of $65.53.

Confirmed

Global impact / market context

A price target is an analyst’s estimate, not a guaranteed outcome. The revised $67 target sits only slightly above the cited closing price, so it signals limited projected share-price gain from that reference point; the rating remains Buy, but the article reports no change to AtriCure’s business or financial results.

Analyst inference

The five recent analyst targets listed range from $62 to $70, placing Canaccord’s $67 target within that spread. This range shows differing views among analysts; targets are estimates and do not establish what the shares will actually be worth or how investors will trade them.

Confirmed

What to watch

  1. Compare future analyst updates with the current $62–$70 target range; changes in those estimates could alter investors’ expectations for AtriCure’s share value. Analyst inference
  2. Watch for company results or guidance in later reporting that could support or challenge the assumptions behind the $67 target; none are provided here. Analyst inference
  3. The article reports Canaccord’s Buy rating and higher target, but gives no details about the analysis or business evidence supporting the revision. Confirmed

Evidence

  • Original source link unavailable